Utility of CINtec PLUS in Identification of High‐Grade Lesions on Short‐Term Follow‐Up in Patients With Negative Cytologic Interpretation
Diagnostic Cytopathology · 2025
DOI: 10.1002/dc.25457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostic Cytopathology, 2025. Verfasst von Niyati Desai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Uterine Cervical Dysplasia, Papillomavirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Screening for cervical cancer may include cervical cytology and/or high‐risk human papillomavirus testing (HPV). The FDA (Food and Drug Administration)‐approved CINtec PLUS dual stain (DS) for p16 and Ki‐67 can provide helpful information for challenging follow‐up care.
Methods
We retrospectively analyzed 272 cases with negative intraepithelial malignancy (NILM) Papanicolaou (Pap) tests and positive HPV test results. All 272 women had colposcopy‐directed biopsies or endocervical curettage (ECC) (histopathology) within a year. We compared DS test results with corresponding ECC/colposcopy specimens. Two subgroup analyses were conducted to examine the correlation of DS results with a prior history of abnormal Pap/colposcopy and to compare DS results with regard to HPV genotype. For analysis purposes, only high‐grade lesions were considered positive, while low‐grade lesions were grouped with negative results.
Results
Of 272 cases, 113 tested positive for DS, while 159 were negative. On follow‐up histopathology within a year, three of the 113 positive cases (2.6%) showed high‐grade lesions. In comparison, none of the 159 negative cases showed any high‐grade lesions (95% confidence interval [CI]: −0.3% to 5.4% [ p = 0.14]). Further analysis by HPV status showed that DS helped in risk discrimination in both subcategories (HPV16/18 and other 12 high‐risk HPV), although it was not statistically significant ( p = 0.99). Subgroup analysis based on the history of high‐grade lesions demonstrated that in cases with no previous history, the risk difference was 2.8% between DS positive and negative results (95% CI −0.3% to 6%, p = 0.134).
Conclusion
All three high‐grade lesions were in the DS positive category, suggesting DS may help in the risk stratification for HPV‐positive NILM women (either HPV16/18 or other). Furthermore, DS may help with risk stratification, specifically in patients with no prior high‐grade lesions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
- St. Luke's University Health Network, Bethlehem, PA, USA.
- Department of Pathology and Laboratory Medicine, University of California Davis Health System, Sacramento, California, USA.
- Norwalk Hospital, Norwalk, Connecticut, USA.
ORCID-Profile: Niyati Desai
Zitieren
APA
Desai, N., Towne, W., Connelly, C. F., Baskota, S. U., Crapanzano, J. P., Desai, K., & Cimic, A. (2025). Utility of CINtec PLUS in Identification of High‐Grade Lesions on Short‐Term Follow‐Up in Patients With Negative Cytologic Interpretation. Diagnostic Cytopathology. https://doi.org/10.1002/dc.25457
Vancouver
Desai N, Towne W, Connelly CF, Baskota SU, Crapanzano JP, Desai K, et al. Utility of CINtec PLUS in Identification of High‐Grade Lesions on Short‐Term Follow‐Up in Patients With Negative Cytologic Interpretation. Diagnostic Cytopathology. 2025. doi:10.1002/dc.25457
BibTeX
@article{Desai2025,
author = {Desai, Niyati and Towne, William and Connelly, Courtney F and Baskota, Swikrity U and Crapanzano, John P and Desai, Kanan and Cimic, Adela},
title = {Utility of CINtec PLUS in Identification of High‐Grade Lesions on Short‐Term Follow‐Up in Patients With Negative Cytologic Interpretation},
journal = {Diagnostic Cytopathology},
year = {2025},
doi = {10.1002/dc.25457}
}
EUVIMED